Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided. The methods comprise administering to the mammal an effective amount of a peptide of the formula: X.sup.1-X.sup.2-X.sup.3 wherein X.sup.1 is selected from the group consisting of 2-amino-hexanoic acid; 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X.sup.2 is an acidic amino acid; and X.sup.3 is an aliphatic amino acid; or of a peptide of the formula: X.sup.4-X.sup.5 wherein X.sup.4 is an aromatic or aliphatic amino acid; and X.sup.5 is an acidic amino acid.

Salpep Biotechnology Inc.

Anti-inflammatory peptides

Salpep Biotechnology, Inc.

Compounds of the formula ##STR1##wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as described in the specification are useful to treat inflammation and other immune disorders.

Pfizer Inc.

Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-.alpha. binding to its CCR 1 receptor

The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trif- luoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR.gamma.) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.

hexanoic/inflammation

Anti-inflammatory peptides

Anti-inflammatory peptides

Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-.alpha. binding to its CCR 1 receptor

Competitive PPAR-gamma antagonists

Baz done ki pi konplè remèd fèy medsin te apiye nan syans